Transtek Medical
Transtek Medical is a Chinese maker of wearable, home medical, and mobile-health electronics, also known through its Lifesense brand.
Last updated October 13, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Transtek Medical, formally Guangdong Transtek Medical Electronics Co., Ltd. and also known as Lifesense, is a Chinese medical-electronics and wearable-device company founded in 2002 by Weichao Pan. Its business combines consumer health hardware with mobile-health applications, covering products such as electronic scales, smart bracelets, blood-pressure monitors, and other devices intended to collect and communicate personal health data. The company developed from a home-health-electronics focus into a broader connected-health business. Its products are associated with weight measurement, activity tracking, heart-rate monitoring, blood-pressure measurement, and related digital health functions. The Lifesense name has been used for several of its consumer-facing wearable products, while the Transtek corporate identity is associated with the company’s wider medical-electronics operations. A notable stage in Transtek’s development came in 2014 with the release of Mambo, a health-tracking device. The company expanded its wearable range in October 2016 with Lifesense Band 2, which included heart-rate data collection. According to IDC figures cited in the company’s Wikipedia coverage, Transtek shipped approximately one million wearable units in the second quarter of 2016, placing it fifth in the worldwide wearable-device market at that time, behind Fitbit, Apple, and Garmin. Transtek pursued a public listing during the same period. Its initial-public-offering application was approved by the China Securities Regulatory Commission in October 2016, and the company began trading on the Shenzhen Stock Exchange on November 16, 2016, under ticker 300562. Great Wall Securities acted as lead underwriter. The listing provided a public-market structure for a company operating at the intersection of consumer electronics, home medical equipment, and digital health. The company continued to develop partnerships and connected-health capabilities after its listing. In October 2017, it signed a cooperation agreement with Cooper Aerobics, a United States-based organization focused on preventive medicine and fitness. In December 2017, Transtek established a medical-industry fund, indicating an effort to participate more broadly in healthcare-related investment and industry development. In 2019, it introduced a proprietary line of smart sports watches, extending beyond basic activity bands into a more feature-rich wearable category. Regulatory progress also supported its medical-device activities. Transtek’s blood-pressure monitors received United States Food and Drug Administration 510(k) clearance in March 2021. This clearance is relevant to the company’s expansion of regulated home-health products, although the available reference material does not specify the cleared models, distribution arrangements, or subsequent sales performance. Transtek Medical’s positioning is therefore built around accessible personal health monitoring and connected medical electronics rather than a single flagship consumer product. Its portfolio spans everyday wellness devices and more clinically oriented home-monitoring equipment. Public information supplied for this entry does not establish the company’s headquarters, current executives, official website, detailed revenue profile, or current geographic sales breakdown. Regulatory progress also supported its medical-device activities. Transtek’s blood-pressure monitors obtained FDA 510(k) clearance in March 2021. This clearance was relevant to the company’s expansion of regulated home-health products, although the available references do not specify the cleared model, distribution arrangements, or subsequent sales performance.
History
Transtek Medical was founded in 2002 by Weichao Pan in China. The company’s formal corporate name is Guangdong Transtek Medical Electronics Co., Ltd., while Transtek and Lifesense are used as shorter or consumer-facing names. Its initial and continuing business has centered on home medical and health electronics, including electronic scales, wearable activity devices, and blood-pressure monitors. During the 2010s, Transtek expanded into connected wearables and mobile health. In 2014, it released Mambo, a health-tracking product. The company’s wearable activity accelerated by 2016. IDC data cited in reference material placed Transtek’s shipments at approximately one million wearable units in the second quarter of that year, ranking it fifth in the global wearable-device market behind Fitbit, Apple, and Garmin. In October 2016, Transtek introduced the Lifesense Band 2, which added heart-rate data collection to its wearable offering. Transtek also pursued access to public capital. The China Securities Regulatory Commission approved its IPO application in October 2016. On November 16 of that year, the company listed on the Shenzhen Stock Exchange under ticker 300562.SZ, with Great Wall Securities serving as lead underwriter. The listing marked a transition from a privately operated medical-electronics company to a publicly traded enterprise. After listing, the company continued to develop external relationships and broaden its healthcare involvement. On October 10, 2017, it signed a cooperation agreement with Cooper Aerobics in the United States. In December 2017, it established a medical-industry fund. These activities complemented its hardware business by connecting the brand with preventive health, fitness, and wider medical-industry development. In 2019, Transtek launched its own smart sports-watch brand, giving it a presence in a more advanced wearable segment. Its product scope remained divided between consumer wellness devices and home medical equipment. The latter category received an important regulatory milestone in March 2021, when Transtek’s blood-pressure monitors obtained FDA 510(k) clearance in the United States. The available source material presents Transtek as a company operating across wearable technology, home medical monitoring, and mobile health. It does not provide sufficient information to document later product generations, current management, headquarters, detailed ownership arrangements, revenue, or the precise markets in which each product is sold.
- 2021
Blood-pressure monitors receive FDA 510(k) clearance
[1]Transtek’s blood-pressure monitors received FDA 510(k) clearance in March.
- 2019
Smart sports-watch brand launched
[1]Transtek introduced its own smart sports-watch brand.
- 2017
Cooperation agreement with Cooper Aerobics
[1]Transtek signed a cooperation agreement with Cooper Aerobics on October 10.
- 2017
Medical-industry fund established
[1]The company created a fund focused on the medical industry in December.
- 2016
Wearable shipments reach a leading global position
[1]IDC data cited in the reference material recorded approximately one million Transtek wearable shipments in the second quarter, placing the company fifth globally.
- 2016
Lifesense Band 2 introduced
[1]The Lifesense Band 2 launched with heart-rate data collection.
- 2016
IPO approved and Shenzhen listing completed
[1]The CSRC approved Transtek’s IPO application in October, and the company listed on the Shenzhen Stock Exchange on November 16 under 300562.SZ.
- 2014
Mambo health tracker released
[1]Transtek introduced Mambo, a health-tracking device that formed part of its wearable-device expansion.
- 2002
Company founded
[1]Weichao Pan founded Transtek Medical in China.
Products and positioning
A Chinese connected-health and medical-electronics brand combining consumer wearables with home medical monitoring, mobile-health functions, and regulated health devices.
Health-tracking wearable · 2014
Mambo
Mambo is a health-tracking device released by Transtek in 2014. It represents the company’s early move into wearable and connected personal-health products. The available reference does not identify its full sensor package, software functions, price, or subsequent product generations.
Smart bracelet · 2016
Lifesense Band 2
Lifesense Band 2 is a wearable bracelet introduced in October 2016. Its cited distinguishing feature was the collection of heart-rate data, extending the product beyond basic activity tracking. The reference material does not specify its operating system compatibility, battery life, clinical status, or current availability.
Smart sports watch · 2019
Lifesense smart sports watches
Transtek launched its own smart sports-watch brand in 2019. The line broadened the company’s wearable portfolio from bracelets and trackers into watch-format devices intended for sports and personal-health use. Specific models, functions, markets, and present availability are not identified in the supplied sources.
Home medical monitoring device
Blood-pressure monitors
Transtek’s blood-pressure monitors are part of its home medical-electronics portfolio. The products obtained FDA 510(k) clearance in March 2021, a regulatory milestone indicating that the cited devices were cleared for marketing in the United States under the applicable substantial-equivalence pathway. The source does not identify individual model numbers.
Home health electronics
Electronic scales
Electronic scales are among Transtek Medical’s principal home-health products. They fit the company’s broader connected-health positioning by bringing routine body or weight measurement into a portfolio that also includes wearables and medical monitors. The supplied reference does not provide model names, launch dates, connectivity specifications, or current status.
Controversies
Brand decisions
2021
FDA 510(k) clearance for blood-pressure monitorsOtherBackground
Transtek was seeking to develop and market home medical devices alongside consumer wellness products.
Action taken
The company obtained FDA 510(k) clearance for its blood-pressure monitors in March 2021.
Aftermath
The clearance supported the regulatory standing of the cited monitors in the United States, although the source does not specify model numbers or distribution results.
2019
Expansion into smart sports watchesProduct launchBackground
The company’s earlier portfolio included health trackers and smart bracelets, while the wearable market was moving toward multifunctional watch-format products.
Action taken
Transtek launched its own smart sports-watch brand.
Aftermath
The move extended Transtek’s wearable-device coverage; specific models and market performance are not documented in the available sources.
2017
Cooperation with Cooper AerobicsStrategyBackground
Transtek was developing links between connected devices, fitness, preventive health, and medical applications.
Action taken
The company signed a cooperation agreement with United States-based Cooper Aerobics on October 10.
Aftermath
The supplied sources do not describe the agreement’s specific deliverables or commercial outcome.
2017
Creation of a medical-industry fundStrategyBackground
Transtek operated across consumer wearables and home medical electronics and sought broader participation in healthcare-related activities.
Action taken
The company established a medical-industry fund in December 2017.
Aftermath
No investment amounts, portfolio companies, or subsequent outcomes are identified in the supplied material.
2016
Launch of Lifesense Band 2Product launchBackground
Transtek was expanding rapidly in wearable devices and had achieved a high global shipment ranking in the second quarter of 2016.
Action taken
The company introduced Lifesense Band 2 with heart-rate data collection.
Aftermath
The launch strengthened Transtek’s wearable portfolio, although the supplied sources do not document sales or later commercial results.
2016
Public listing on the Shenzhen Stock ExchangeStrategyBackground
Transtek sought public-market financing as its wearable and medical-electronics activities expanded.
Action taken
Following IPO approval in October, the company listed on November 16 under ticker 300562.SZ.
Aftermath
The listing made Transtek a publicly traded company; the available material does not state the offering size or use of proceeds.
Recent events
- 2021
Transtek blood-pressure monitors receive FDA 510(k) clearance[1]
Regulation
Transtek’s blood-pressure monitors obtained United States FDA 510(k) clearance in March 2021, supporting their positioning as regulated medical devices.
- 2019
Transtek launches its own smart sports-watch brand[1]
Product launch
Transtek introduced a proprietary smart sports-watch line, extending its wearable portfolio beyond bracelets and basic health trackers.
- 2017
Transtek signs cooperation agreement with Cooper Aerobics[1]
Other
The company entered into a cooperation agreement with United States-based Cooper Aerobics, broadening its connections in preventive health and fitness.
- 2017
Transtek establishes a medical-industry fund[1]
Other
In December 2017, Transtek created a fund focused on the medical industry, signaling activity beyond its core hardware business.
- 2016
Transtek ranks among the leading global wearable-device makers[1]
Other
IDC data cited in reference material indicated that Transtek shipped about one million wearable units in the second quarter of 2016, ranking fifth worldwide at the time.
- 2016
Lifesense Band 2 launches with heart-rate collection[1]
Product launch · Product generation
The Lifesense Band 2 expanded Transtek’s wearable range with the ability to collect heart-rate data.
- 2016
Transtek begins trading on the Shenzhen Stock Exchange[1]
Other
Transtek was listed on the Shenzhen Stock Exchange on November 16, 2016, under ticker 300562.SZ after its IPO application received regulatory approval.
- 2014
Transtek releases the Mambo health tracker[1]
Product launch
Transtek introduced Mambo, a health-tracking device that marked an important step in the company’s wearable-product development.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/transtek-medical · Editorial policy · How profiles are compiled